Humana’s Medicare Advantage overhaul involving 600,000 members eclipses Q2 earnings beat
29 July 2026
2 mins read

Humana’s Medicare Advantage overhaul involving 600,000 members eclipses Q2 earnings beat

NEW YORK, July 29, 2026, 16:00 EDT

  • Shares of Humana fell 6.8% to $362.16 approaching the closing bell.
  • Exits set for 2027 could impact 600,000 members. Humana anticipates recapturing roughly 40%.
  • Adjusted profit for the quarter exceeded expectations. Guidance for full-year adjusted earnings was kept at a minimum of $9.00.

Shares of Humana Inc. dropped on Wednesday, even after the company surpassed quarterly profit forecasts. The maintained guidance put the focus on a more substantial Medicare Advantage pullback projected for 2027.

The upcoming departures will impact close to 600,000 Medicare Advantage members. This represents 9.3% of Humana’s 6.454 million individual-plan members as of June. The number also amounts to 49.8% of the 1.204 million members added following December.

Humana anticipates reclaiming approximately 40%, or nearly 240,000 members, through different plans. Nonetheless, the expected churn reflects management’s focus on restoring margins over maintaining volume. Humana is aiming for a stable pretax Medicare Advantage margin of no less than 3% by 2028.

The quarter highlighted the importance of that trade-off.

MeasureCurrent figureComparisonChange or exposure
Consolidated revenue$40.87 billion$32.39 billionup 26.2%
Adjusted EPS$7.61$6.27increased 21.4%
Insurance benefit ratio91.2%89.9%higher by 1.3 percentage points
Adjusted operating-cost ratio9.7%10.9%lower by 1.2 percentage points
Individual MA membership6.454 million5.229 millionjumped 23.4%
Members in planned 2027 exitsAbout 600,000Current individual MA base9.3%

Company disclosures provide the financial and membership data. The 9.3% exposure figure is based on June individual Medicare Advantage enrollment.

Revenue increased at a higher rate than earnings. Adjusted earnings reached $7.61 per share, surpassing the $7.22 LSEG consensus estimate. Despite this, Humana maintained its minimum full-year adjusted EPS outlook at $9.00.

The benefit ratio, representing premiums allocated to care, deteriorated by 1.3 percentage points. Meanwhile, the adjusted operating-cost ratio saw a 1.2-point improvement. Scale continues to benefit overhead, but claims persist as the limiting factor.

Humana reported that new enrollees have higher benefit ratios compared to existing members. An increase in the ratio was also attributed to reduced revenue from Star ratings. Trends in medical and pharmacy costs stayed within the high single-digit range.

Barclays analyst Andrew Mok stated the results “likely fell short of elevated investor expectations.” Humana’s shares had risen roughly 60% in the last three months. Reuters

Stock chart for NYSE:HUM

Peer reports had set higher expectations. UnitedHealth Group Inc. lifted its 2026 guidance on July 16 following improved expense management. Humana kept its main forecast unchanged.

Humana lowered its reported, or GAAP, EPS minimum to $6.52 from $8.36. The company anticipates third-quarter adjusted EPS will be close to negative $1.00. The insurance benefit ratio is projected to increase just above 94%.

Chief Executive Jim Rechtin stated that “the first half of the year went well.” He noted that Humana was aligned with management’s expectations following the previous year’s investor day. SEC

Star ratings continue to be the key factor over time. CMS calculates 2026 ratings to set quality-bonus payouts for 2027. Humana’s initial estimate in October suggested that 20% of its members are enrolled in plans rated four stars or above. The company stated that diversification across contracts is expected to reduce its risk for that payout year.

Risks persist. Humana may not regain as many members as expected. Medical costs could outpace pricing, and uncertainty around Star thresholds may push back margin recovery.

The company’s next scheduled milestone is a virtual investor update taking place on December 10. In the meantime, the composition of the 2027 plan holds greater significance than the latest quarterly outperformance.

TS2 TECH • EXTENDED COVERAGE

Further analysis

Specifically, what changes is Humana making to Medicare Advantage in 2027?

Humana is planning selective Medicare Advantage plan withdrawals and adjustments to benefits for 2027, rather than implementing broad reductions. Roughly 600,000 members are enrolled in the affected plans. The company is discontinuing plans with lower returns to strengthen its more profitable offerings. Investing.com As of July 29, the specific counties impacted and exact changes to supplemental benefits have not been disclosed. The Centers for Medicare & Medicaid Services expects to release final details on 2027 plans and premiums in September. Reuters

What is the size of the exposure affecting 600,000 members?

Humana reported 6.454 million individual MA members and 7.181 million total MA members. The number of exits amounts to 9.3% of individual MA or 8.4% of total MA. SEC During its comparable 2025 exits, management was able to win back just over 40%. Applied here, approximately 240,000 members would transfer into other Humana plans, leaving about 360,000 potentially departing. These calculations are simple estimates and do not reflect Humana’s official 2027 membership forecast. Investing.com

Why reduce plans after CMS increased 2027 Medicare Advantage payments?

CMS approved a net average payment increase of 2.48%, totaling over $13 billion. CMS Humana continues to project medical and pharmacy cost growth at about 7%–8%. These figures are not precisely comparable due to factors such as risk scores and member mix. Based on a simple comparison, costs seem to grow faster than the listed payment increase. Exits are therefore seen as an additional tool to help recover underwriting margins. Investing.com

Are the reductions likely to have a substantial impact on Humana’s Medicare Advantage margin?

Humana aims for a sustainable individual MA pretax margin of at least 3% in 2028. Executives see significant advances coming in 2027, but have not specified a margin figure. Management cited benefit adjustments, plan departures, clinical initiatives, and operational improvements as contributing factors. The outcome in 2027 will largely hinge on the number and mix of members. The overall direction is established. How large the shift will be remains uncertain. Investing.com

Is Humana effectively managing its medical expenses at present?

Humana posted a second-quarter insurance benefit ratio of 91.2%, compared with 89.9% in the same period a year ago. The company maintained its full-year guidance at 92.75%, allowing for a 25 basis point fluctuation. SEC Management reported medical and pharmacy trends remaining within their projected 7%–8% range, noting marginal inpatient improvement, mainly for value-based plan members. The buffer remains slim. For the third quarter, the company forecast the ratio slightly above 94%. Investing.com

Is the present pace of membership growth sufficient to balance out plan departures in 2027?

Humana’s individual MA membership climbed to 6.454 million, representing a 23% rise from a year earlier. The company maintains its projection for approximately 25% growth in individual MA membership for the full year 2026. SEC This growth results in a larger base ahead of expected reductions in 2027. The planned 600,000 departures account for about half of the 1.204 million membership gains seen in the year’s first half. Net membership figures in 2027 will now depend on both retention and recapture. Investing.com

What is the extent of the risk posed to Humana by its Medicare Star Ratings?

Humana’s adjusted EPS floor is set at $9, down from the $17.14 reported in 2025. The company points to 2026 Stars-related bonus pressure as the cause of the drop. SEC Humana reports operational improvement exceeded historical averages in 11 out of 12 chosen metrics. However, CMS thresholds have yet to be disclosed. No outcomes are assured. Investing.com A district-court lawsuit did not succeed, but an appeal is still under review. The forthcoming CMS ratings release in October is the next significant milestone. SEC

What caused HUM shares to decline after surpassing quarterly expectations?

Humana posted adjusted earnings per share of $7.61, surpassing the $7.22 consensus estimate. Revenue was $40.87 billion, an increase of 26% from the prior year. The company maintained its adjusted full-year outlook at a minimum of $9 per share. GAAP full-year guidance was reduced to at least $6.52, down from $8.36 per share. SEC The latest available July 29 closing price was $362.51, representing a 6.7% decline. Investors anticipated more after the stock surged nearly 60% in the last three months. Reuters

Does the modification to the Part D subsidy fall under these MA reductions?

These are distinct Medicare updates. CMS will discontinue the voluntary premium-stabilization program after 2026. The national average monthly bid for 2027 is $296.05. The base beneficiary premium stands at $41.33, with final information set for September. According to CMS, most beneficiaries should see increases of under $10. Reuters Humana reports that members will feel a greater impact than its earnings. Investing.com

What is a realistic projection for HUM shares over the upcoming twelve months?

In late U.S. trading on July 29, HUM traded at $362.51, down 6.7%. According to MarketWatch, the consensus for 2027 EPS is $16.16, with a price target of $355.54. MarketWatch These estimates could be revised after July 29; this forecast should not be taken as guidance. Applying a 20–24x multiple to projected EPS produces a base valuation range of $323–$388. The base twelve-month range is $325–$390, with a midpoint close to $358. If Stars recovery and recapture trends exceed expectations, the upside scenario reaches $450–$500. If costs rise or attrition deteriorates, a downside case targets $240–$300. Investing.com

Roman Perkowski is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Cracow University of Economics, he previously worked in investment research and corporate finance. His coverage helps readers understand the key forces driving global financial markets and emerging industries. Follow Roman Perkowski on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY IN STAGES

AerCap

NYSE: AER 95 / 100
#2 BUY ON WEAKNESS

Xylem

NYSE: XYL 93 / 100
#3 ACCUMULATE

General Dynamics

NYSE: GD 91 / 100
#4 BUY WITH LIMITS

Visa

NYSE: V 88 / 100
#5 TACTICAL BUY

IDEX

NYSE: IEX 85 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Hims & Hers (NYSE:HIMS) Stock Drops 12% as FTC Suit Tests Marketing Engine
Previous Story

Hims & Hers (NYSE:HIMS) Stock Drops 12% as FTC Suit Tests Marketing Engine

TeraWulf (NASDAQ:WULF) Stock Gains for Week; Anthropic Lease Implies 28% More Revenue per Megawatt
Next Story

TeraWulf (NASDAQ:WULF) drops 12% amid investor activity similar to AI sector moves